Edition:
United States

Akebia Therapeutics Inc (AKBA.OQ)

AKBA.OQ on NASDAQ Stock Exchange Global Market

8.28USD
21 Sep 2018
Change (% chg)

$-0.05 (-0.60%)
Prev Close
$8.33
Open
$8.36
Day's High
$8.41
Day's Low
$7.96
Volume
620,776
Avg. Vol
162,845
52-wk High
$20.25
52-wk Low
$7.34

Latest Key Developments (Source: Significant Developments)

Akebia Therapeutics Announces Pricing Of Public Offering Of Common Stock
Friday, 23 Mar 2018 08:00am EDT 

March 23 (Reuters) - Akebia Therapeutics Inc ::AKEBIA THERAPEUTICS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 8.50 MILLION COMMON SHARES PRICED AT $10.50PER SHARE.  Full Article

Akebia Therapeutics Announces Proposed Public Offering Of Common Stock
Thursday, 22 Mar 2018 04:26pm EDT 

March 22 (Reuters) - Akebia Therapeutics Inc ::AKEBIA THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.AKEBIA THERAPEUTICS INC - INTENDS TO OFFER AND SELL APPROXIMATELY $85 MILLION OF SHARES OF ITS COMMON STOCK IN AN UNDERWRITTEN PUBLIC OFFERING.AKEBIA - ‍INTENDS TO USE NET PROCEEDS FROM OFFERING FOR CONTINUED CLINICAL DEVELOPMENT, OPTIMIZATION OF VADADUSTAT PROGRAM.  Full Article

Akebia Therapeutics Announces Q4 Earnings Per Share $0.25
Monday, 12 Mar 2018 04:03pm EDT 

March 12 (Reuters) - Akebia Therapeutics Inc ::AKEBIA THERAPEUTICS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2017 FINANCIAL RESULTS.Q4 EARNINGS PER SHARE $0.25.Q4 EARNINGS PER SHARE VIEW $-0.35 -- THOMSON REUTERS I/B/E/S.AKEBIA THERAPEUTICS - EXPECTS EXISTING CASH RESOURCES TO FUND CURRENT OPERATING PLAN INTO Q2 2019.QTRLY COLLABORATION REVENUE $87.3 MILLION VERSUS $1.5 MILLION.EXPECTS EXISTING CASH RESOURCES WITH OTHERS TO FUND ITS CURRENT OPERATING PLAN INTO Q2 OF 2019.  Full Article

Akebia Therapeutics Announces Positive Results From Study Of Vadadustat In Japanese
Thursday, 4 Jan 2018 07:00am EST 

Jan 4 (Reuters) - Akebia Therapeutics Inc ::AKEBIA THERAPEUTICS ANNOUNCES POSITIVE TOP-LINE RESULTS FROM PHASE 2 STUDY OF VADADUSTAT IN JAPANESE PATIENTS WITH ANEMIA ASSOCIATED WITH DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE.DATA CONSISTENT WITH FINDINGS FROM PREVIOUS STUDIES​.‍PHASE 3 STUDY OF NON-DIALYSIS PATIENTS IN JAPAN ONGOING; PHASE 3 STUDIES OF DIALYSIS PATIENTS TO BEGIN IN 2018​.STATISTICALLY SIGNIFICANT IMPROVEMENTS IN PRIMARY ENDPOINT OBSERVED IN VADADUSTAT GROUP 150 MG (P = 0.0004) COMPARED TO PLACEBO​.STATISTICALLY SIGNIFICANT IMPROVEMENTS ALSO OBSERVED IN VADADUSTAT GROUPS 300 MG(P<0.0001), 600 MG(P< 0.0001),COMPARED TO PLACEBO​.SERIOUS ADVERSE EVENTS WERE CONSISTENT WITH PRIOR STUDIES.NO DEATHS WERE REPORTED.  Full Article

Akebia Therapeutics reports Q3 loss per share $0.49
Wednesday, 8 Nov 2017 04:05pm EST 

Nov 8 (Reuters) - Akebia Therapeutics Inc :Akebia Therapeutics announces third quarter 2017 financial results.Q3 loss per share $0.49.Q3 earnings per share view $-0.51 -- Thomson Reuters I/B/E/S.Akebia Therapeutics Inc -cash, cash equivalents and available for sale securities $329.7 million at sept 30 versus $260.3 million as at dec 31, 2016​.  Full Article

Akebia announces positive top-line results from phase 2 study of vadadustat in Japanese patients
Tuesday, 26 Sep 2017 07:00am EDT 

Sept 26 (Reuters) - Akebia Therapeutics Inc :Akebia announces positive top-line results from phase 2 study of vadadustat in Japanese patients with non-dialysis-dependent chronic kidney disease.Says ‍phase 3 study in Japan expected to commence by year-end 2017​.Says co provides Mitsubishi Tanabe with option to access global phase 3 vadadustat data for payments of up to $25 million​.Says ‍results confirm findings from previous studies of vadadustat​.Akebia Therapeutics Inc says MTPC will be responsible for all costs associated with phase 3 vadadustat program in Japan.Akebia Therapeutics Inc says expects to submit a Japanese New Drug Application (JNDA) for vadadustat with an anticipated launch in 2020..  Full Article

Muneer Satter reports 6.48 pct stake in Akebia Therapeutics
Friday, 14 Jul 2017 05:16pm EDT 

July 14 (Reuters) - Akebia Therapeutics Inc :Muneer Satter reports 6.48 percent stake in Akebia Therapeutics Inc as of July 5 - SEC filing.Muneer Satter says acquired common stock of Akebia Therapeutics Inc for investment purposes.  Full Article

Akebia prices public offering of 4 mln shares at $14.50/share
Wednesday, 28 Jun 2017 10:46pm EDT 

June 28 (Reuters) - Akebia Therapeutics Inc ::Akebia announces pricing of public offering of common stock.Pricing of an underwritten public offering of 4 million shares of common stock at a price to public of $14.50 per share.  Full Article

Akebia Therapeutics announces proposed public offering of common stock
Wednesday, 28 Jun 2017 04:15pm EDT 

June 28 (Reuters) - Akebia Therapeutics Inc :Akebia Therapeutics announces proposed public offering of common stock.Akebia Therapeutics Inc - intends to use net proceeds from offering for continued clinical development of vadadustat, among others.  Full Article

Vifor Pharma reports 8.4 pct stake in Akebia Therapeutics
Monday, 22 May 2017 04:20pm EDT 

May 22 (Reuters) - Akebia Therapeutics Inc ::Vifor Pharma Ltd reports a 8.4 percent stake in Akebia Therapeutics Inc as of May 12, 2017 - sec filing.  Full Article

Photo

Ex-Akebia employee jailed for night as insider trading trial starts

BOSTON A former Akebia Therapeutics Inc employee accused of engaging in an insider trading scheme must spend a night in jail after he violated a U.S. judge's order and spoke to a witness at the start of his trial on Tuesday.